The compiled results in Table 1 indicate that some functional polymorphisms affecting the enzymatic activities of CYP2D6, CYP3A5, CYP2C8, CYP2C19, SULT1A1, or UGT2B15 could significantly affect breast cancer outcomes. This evidence concerns the gene CYP3A5 and breast cancer.